^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

TRAIL R2 agonist

Phase 1
AbbVie
Completed
Last update posted :
12/09/2022
Initiation :
03/20/2017
Primary completion :
01/21/2022
Completion :
01/21/2022
KRAS
|
KRAS mutation • RAS mutation
|
Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)
Phase 1
NYU Langone Health
Completed
Last update posted :
10/18/2021
Initiation :
10/01/2016
Primary completion :
12/23/2019
Completion :
01/01/2021
IL2
|
Opdivo (nivolumab) • DS-8273
Phase 2
Daiichi Sankyo, Inc.
Completed
Last update posted :
04/08/2021
Initiation :
07/09/2010
Primary completion :
07/13/2012
Completion :
09/09/2013
AFP
|
sorafenib • tigatuzumab (CS-1008)
Phase 1
Hoffmann-La Roche
Completed
Last update posted :
04/04/2018
Initiation :
10/11/2015
Primary completion :
11/06/2017
Completion :
11/06/2017
FAP
|
FAP expression
Phase 2
University of Alabama at Birmingham
Completed
Last update posted :
10/26/2017
Initiation :
03/01/2011
Primary completion :
06/01/2016
Completion :
06/01/2017
HER-2 • PGR
|
HER-2 amplification • HER-2 negative
|
albumin-bound paclitaxel • tigatuzumab (CS-1008)
Phase 2
Genentech, Inc.
Completed
Last update posted :
06/06/2017
Initiation :
03/01/2008
Primary completion :
12/01/2009
Completion :
12/01/2009
CD20
|
CD20 positive
|
Rituxan (rituximab) • drozitumab (RG7425)
Phase 3
Shanghai Gebaide Biotechnology Co., Ltd.
Unknown status
Last update posted :
03/20/2017
Initiation :
10/01/2016
Primary completion :
10/01/2017
Completion :
06/01/2018
ALK
|
EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative
|
dulanermin (AMG 951)
Phase 1b
TetraLogic Pharmaceuticals
Completed
Last update posted :
01/14/2016
Initiation :
11/01/2013
Primary completion :
09/01/2015
Completion :
12/01/2015
MUC16
|
birinapant (IGM-9427) • conatumumab (AMG 655)